Rokote Laboratories Finland Oy is proud to announce that we have received Clinical Trial Authorization (CTA) for our second Phase I clinical trial of the intranasal COVID-19 vaccine.
The upcoming study, titled:
“A Phase 1a, single-blind, randomized comparative clinical trial evaluating the impact of vaccine formulation on the safety and immunogenicity of the COV2 vaccine in healthy adults,”
will compare a novel vaccine formulation developed by our team with our previously used formulation. This represents a major step forward in the development of our universal intranasal vaccine platform.
The second-generation nasal FINVAC COVID-19 vaccine, developed and manufactured in Finland, is designed to create strong immune protection at the site of viral entry, preventing the coronavirus from attaching, multiplying, and ultimately causing disease. The Phase I trial will evaluate the vaccine’s safety and immunogenicity administered as a nasal spray. Healthy volunteers aged 18–75 will participate.
Nasal administration allows broad and efficient population vaccination. The ease of nasal delivery makes it possible to vaccinate large groups with fewer resources, an important advantage for ongoing and future public health needs.
During development, the vaccine technology was designed to be adaptable for future pandemics. Should SARS-CoV-2 or other viruses mutate to pose greater risks, the platform allows for rapid updates and deployment.
With CTA approval now secured, we are excited to begin our second clinical trial in January 2026. Detailed information on participant recruitment will be shared shortly after the New Year.